Moloney Securities Asset Management LLC Has $1.33 Million Holdings in Abbott Laboratories (ABT)

Moloney Securities Asset Management LLC raised its position in shares of Abbott Laboratories (NYSE:ABT) by 4.1% during the second quarter, according to its most recent Form 13F filing with the Securities & Exchange Commission. The fund owned 27,369 shares of the healthcare product maker’s stock after acquiring an additional 1,089 shares during the period. Moloney Securities Asset Management LLC’s holdings in Abbott Laboratories were worth $1,330,000 as of its most recent filing with the Securities & Exchange Commission.

A number of other hedge funds have also recently bought and sold shares of the business. State Street Corp boosted its stake in shares of Abbott Laboratories by 18.9% during the first quarter. State Street Corp now owns 80,499,469 shares of the healthcare product maker’s stock valued at $3,574,987,000 after purchasing an additional 12,806,535 shares during the period. Boston Partners boosted its stake in shares of Abbott Laboratories by 5,663.7% during the first quarter. Boston Partners now owns 8,212,035 shares of the healthcare product maker’s stock valued at $364,696,000 after purchasing an additional 8,069,557 shares during the period. Bank of New York Mellon Corp boosted its stake in shares of Abbott Laboratories by 11.0% during the first quarter. Bank of New York Mellon Corp now owns 33,796,869 shares of the healthcare product maker’s stock valued at $1,500,920,000 after purchasing an additional 3,344,508 shares during the period. Ameriprise Financial Inc. boosted its stake in shares of Abbott Laboratories by 33.8% during the first quarter. Ameriprise Financial Inc. now owns 8,823,399 shares of the healthcare product maker’s stock valued at $391,841,000 after purchasing an additional 2,231,316 shares during the period. Finally, Swiss National Bank boosted its stake in shares of Abbott Laboratories by 45.3% during the first quarter. Swiss National Bank now owns 6,528,788 shares of the healthcare product maker’s stock valued at $289,943,000 after purchasing an additional 2,035,170 shares during the period. Institutional investors and hedge funds own 71.66% of the company’s stock.

Abbott Laboratories (NYSE:ABT) traded down 1.0215% during mid-day trading on Tuesday, reaching $51.9142. 2,184,377 shares of the company were exchanged. The stock’s 50-day moving average price is $49.78 and its 200-day moving average price is $46.72. The stock has a market capitalization of $90.20 billion, a price-to-earnings ratio of 72.7090 and a beta of 1.06. Abbott Laboratories has a 1-year low of $37.38 and a 1-year high of $52.54.

Abbott Laboratories (NYSE:ABT) last released its earnings results on Thursday, July 20th. The healthcare product maker reported $0.62 earnings per share for the quarter, beating the consensus estimate of $0.60 by $0.02. The company had revenue of $6.64 billion during the quarter, compared to the consensus estimate of $6.63 billion. Abbott Laboratories had a return on equity of 14.43% and a net margin of 4.96%. Abbott Laboratories’s revenue was up 24.5% compared to the same quarter last year. During the same period in the previous year, the company posted $0.55 EPS. On average, equities research analysts anticipate that Abbott Laboratories will post $2.49 EPS for the current fiscal year.

In other news, insider Brian J. Blaser sold 15,000 shares of Abbott Laboratories stock in a transaction dated Thursday, July 27th. The stock was sold at an average price of $50.00, for a total value of $750,000.00. Following the completion of the transaction, the insider now owns 143,154 shares in the company, valued at approximately $7,157,700. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this link. Also, insider Hubert L. Allen sold 4,600 shares of Abbott Laboratories stock in a transaction dated Tuesday, July 25th. The shares were sold at an average price of $50.79, for a total value of $233,634.00. Following the completion of the transaction, the insider now owns 105,479 shares of the company’s stock, valued at approximately $5,357,278.41. The disclosure for this sale can be found here. Over the last ninety days, insiders sold 218,702 shares of company stock valued at $10,837,658. 0.76% of the stock is currently owned by corporate insiders.

TRADEMARK VIOLATION WARNING: This report was originally published by Stock Observer and is owned by of Stock Observer. If you are viewing this report on another website, it was illegally stolen and republished in violation of US and international trademark & copyright laws. The original version of this report can be accessed at https://www.thestockobserver.com/2017/09/12/moloney-securities-asset-management-llc-has-1-33-million-holdings-in-abbott-laboratories-abt.html.

ABT has been the subject of a number of recent analyst reports. Royal Bank Of Canada reissued a “buy” rating on shares of Abbott Laboratories in a research note on Monday, May 15th. Goldman Sachs Group, Inc. (The) initiated coverage on shares of Abbott Laboratories in a research note on Tuesday, May 16th. They set a “neutral” rating and a $45.00 target price for the company. Zacks Investment Research raised shares of Abbott Laboratories from a “hold” rating to a “buy” rating and set a $49.00 target price for the company in a research note on Tuesday, May 16th. TheStreet lowered shares of Abbott Laboratories from a “b” rating to a “c+” rating in a research note on Thursday, May 18th. Finally, Stifel Nicolaus boosted their target price on shares of Abbott Laboratories from $49.00 to $51.00 and gave the company a “buy” rating in a research note on Wednesday, May 31st. Seven research analysts have rated the stock with a hold rating and nine have assigned a buy rating to the stock. The company presently has a consensus rating of “Buy” and a consensus target price of $52.50.

Abbott Laboratories Profile

Abbott Laboratories is engaged in the discovery, development, manufacture and sale of a range of healthcare products. The Company operates through four segments: Established Pharmaceutical Products, Diagnostic Products, Nutritional Products and Vascular Products. Its Established Pharmaceutical Products include a range of branded generic pharmaceuticals manufactured around the world and marketed and sold outside the United States.

Want to see what other hedge funds are holding ABT? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Abbott Laboratories (NYSE:ABT).

Institutional Ownership by Quarter for Abbott Laboratories (NYSE:ABT)

Receive News & Ratings for Abbott Laboratories Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Abbott Laboratories and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply